Everest Medicines Limited (HKG:1952)

Everest Medicines Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,518	1,844	884.47	523.06	490.79	2,640
Short-Term Investments	340.81	887.09	719.11	1,827	1,161	-
Cash & Short-Term Investments	2,036	2,731	1,604	2,350	1,651	2,640
Cash Growth	28.36%	70.34%	-31.75%	42.29%	-37.45%	-41.11%
Accounts Receivable	691.61	500.02	363.57	49.86	5.21	0.05
Other Receivables	-	48.55	24.69	81.96	1,681	19.52
Receivables	691.61	548.56	388.26	131.81	1,687	19.57
Inventory	151.36	32.22	14.08	18.94	11.64	0.45
Other Current Assets	138.97	61.29	9.71	7.16	64.6	27.86
Total Current Assets	3,018	3,374	2,016	2,508	3,414	2,688
Property, Plant & Equipment	671.65	656.51	650.04	683.99	643.86	262.64
Long-Term Investments	262.1	302.1	29.71	48.93	89.24	830.4
Other Intangible Assets	3,412	2,091	2,254	2,524	2,378	2,471
Long-Term Deferred Tax Assets	269.23	299.52	-	-	-	-
Other Long-Term Assets	161.46	99.6	6.6	6.12	86.69	391.44
Total Assets	8,445	6,835	4,959	5,773	6,615	6,646

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	493.9	455.98	175.07	95.48	107.52	85.66
Accrued Expenses	-	95.79	94.98	73.51	182.07	133.79
Short-Term Debt	281.29	-	-	-	-	-
Current Portion of Long-Term Debt	-	74.44	470.21	51.28	424.08	-
Current Portion of Leases	24.73	19.48	18.78	18.65	20.33	28.25
Current Income Taxes Payable	-	13.19	2.82	-	-	-
Other Current Liabilities	-	30.74	31.68	89.82	136.03	22.56
Total Current Liabilities	799.93	689.61	793.54	328.74	870.03	270.27
Long-Term Debt	1,640	792.12	55.85	429.31	30.92	387.71
Long-Term Leases	43.6	40.25	30.77	40	59.31	95.85
Long-Term Unearned Revenue	5.67	5.74	5.9	6.05	-	-
Other Long-Term Liabilities	656.81	3.5	-	-	-	-
Total Liabilities	3,216	1,531	886.05	804.1	960.26	753.83

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.24	0.24	0.22	0.22	0.21	0.2
Retained Earnings	-10,560	-10,554	-10,058	-9,016	-8,172	-7,925
Treasury Stock	-	-	-	-0	-0	-58.71
Comprehensive Income & Other	15,789	15,858	14,130	13,985	13,826	13,875
Shareholders' Equity	5,229	5,304	4,073	4,969	5,654	5,892
Total Liabilities & Equity	8,445	6,835	4,959	5,773	6,615	6,646

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,990	926.28	575.61	539.24	534.64	511.81
Net Cash (Debt)	45.98	1,805	1,028	1,810	1,117	2,128
Net Cash Growth	-94.60%	75.61%	-43.22%	62.12%	-47.53%	-46.99%
Net Cash Per Share	0.14	5.37	3.20	5.78	3.75	7.26
Filing Date Shares Outstanding	297.2	351.34	324.35	319.36	305.46	294.41
Total Common Shares Outstanding	297.2	351.34	324.35	319.36	305.46	294.41
Working Capital	2,218	2,684	1,222	2,179	2,544	2,418
Book Value Per Share	17.60	15.10	12.56	15.56	18.51	20.01
Tangible Book Value	1,166	3,213	1,818	2,445	3,276	3,421
Tangible Book Value Per Share	3.92	9.14	5.61	7.66	10.72	11.62
Buildings	-	460.38	461.02	437.87	378.28	-
Machinery	-	188.33	179.16	167.32	84.66	5.72
Construction In Progress	-	41.83	-	9.79	45.75	102.91
Leasehold Improvements	-	58.1	48.17	46.9	44.77	15.91

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 20, 2026

Data Sources Report a data error